You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)"依託考昔片"獲藥品註冊證書
格隆匯 01-04 16:37

格隆匯 1 月 4日丨中國生物製藥(01177.HK)公吿,集團開發的口服鎮痛藥"依託考昔片"(商品名:凱昔)(規格:30mg及60mg)已獲中華人民共和國國家藥品監督管理局頒發藥品註冊證書,且視同通過仿製藥質量和療效一致性評價。

依託考昔是最新一代的選擇性環氧化酶-2(COX-2)抑制劑,具有抗炎、鎮痛和解熱作用,胃腸道不良反應較小,適用於治療骨關節炎急性期和慢性期的症狀和體徵、治療急性痛風性關節炎和原發性痛經。《美國風濕病學會痛風診治指南》推薦使用依託考昔於急性痛風性關節炎的治療。《中國骨關節炎診治指南》以及中華醫學會骨科學分會的《骨科疼痛處理專家意見》推薦有胃腸道風險的患者選用選擇性COX-2抑制劑,可使用依託考昔。

該品種的獲批將可補充和增強集團在鎮痛領域非甾體抗炎藥產品線的佈局,為廣大疼痛患者減輕痛苦並帶來治療上更多的選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account